Arctic Bioscience Future Growth
Future criteria checks 2/6
Arctic Bioscience's earnings are forecast to decline at 12.8% per annum while its annual revenue is expected to grow at 35.6% per year. EPS is expected to decline by 12.7% per annum.
Key information
-12.8%
Earnings growth rate
-12.7%
EPS growth rate
| Biotechs earnings growth | 12.2% |
| Revenue growth rate | 35.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Oct 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 55 | -59 | -40 | -34 | 1 |
| 12/31/2024 | 41 | -53 | -56 | -51 | 1 |
| 6/30/2024 | 32 | -48 | -60 | -38 | N/A |
| 3/31/2024 | 33 | -47 | -73 | -39 | N/A |
| 12/31/2023 | 34 | -46 | -86 | -40 | N/A |
| 9/30/2023 | 36 | -43 | -85 | -37 | N/A |
| 6/30/2023 | 39 | -40 | -85 | -34 | N/A |
| 3/31/2023 | 37 | -37 | -84 | -30 | N/A |
| 12/31/2022 | 34 | -34 | -84 | -25 | N/A |
| 9/30/2022 | 29 | -35 | -80 | -28 | N/A |
| 6/30/2022 | 24 | -36 | -76 | -30 | N/A |
| 3/31/2022 | 23 | -39 | -76 | -35 | N/A |
| 12/31/2021 | 22 | -43 | -76 | -39 | N/A |
| 9/30/2021 | 23 | -38 | -71 | -36 | N/A |
| 6/30/2021 | 25 | -34 | -66 | -32 | N/A |
| 3/31/2021 | 23 | -28 | -51 | -27 | N/A |
| 12/31/2020 | 21 | -23 | -35 | -22 | N/A |
| 12/31/2019 | 30 | -4 | N/A | N/A | N/A |
| 12/31/2018 | 25 | -2 | N/A | N/A | N/A |
| 12/31/2017 | 18 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABS's revenue (35.6% per year) is forecast to grow faster than the Norwegian market (2.2% per year).
High Growth Revenue: ABS's revenue (35.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABS's Return on Equity is forecast to be high in 3 years time